Cost-effectiveness analysis of interferon α-2b with ribavirin for chronic hepatitis C infection

Formulary

Volumn 35, Issue 8, 2000, Pages 681-689

  Malone, Daniel C ^b   Armstrong, Edward P ^a   Grizzle, Amy J ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; CONSENSUS INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; ECONOMIC ASPECT; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICARE; MONOTHERAPY; MORBIDITY; MORTALITY; PREVALENCE; REVIEW;

EID: 0033903538     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:28-9S.
3. Anonymous. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 1999; 49:425-7.
4. Hall, CT. Hepatitis C: Growing chorus of concern over the 'silent' epidemic. San Francisco Chronicle. August 7, 1998:A1.
5. Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1):35-47.
6. McHutchison J. Hepatitis C therapy in treatment-naive patients. Am J Med 1999;107:56S-61S.
7. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
8. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology 1995;22:1863-73.
9. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65.
10. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
11. Davis GL, Beck JR, Farrell G, Poynard T. Prolonged treatment with Interferon in patients with histologically mild chronic hepatitis C: A decision analysis. J Viral Hepat 1998;5:313-21.
12. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs. JAMA 1998;280:2088-93.
13. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-24.
14. Cook R. Prison hepatitis soaring: Authorities expect a sixfold increase by June; treatment of disease is costly and uncertain. Atlanta Constitution. October 12, 1999:1C.
15. Anonymous. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997;26(Suppl 1):2S-10S.
16. Shiell A, Briggs A, Farrell GC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994;160:268-72.
17. Kim WR, Poterucha JJ, Gross JB Jr. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C [letter]. Hepatology 2000;31:807-8.